A5068713545- Intraperitoneal and Appendiceal Malignancies
- Ovarian cancer diagnosis and treatment
- Appendicitis Diagnosis and Management
- Cancer Genomics and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
- Gastric Cancer Management and Outcomes
- Occupational and environmental lung diseases
- Parathyroid Disorders and Treatments
- Abdominal Surgery and Complications
- Colorectal Cancer Treatments and Studies
- Sarcoma Diagnosis and Treatment
- Intestinal and Peritoneal Adhesions
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Central Venous Catheters and Hemodialysis
- Neuroendocrine Tumor Research Advances
- Vascular anomalies and interventions
- Enhanced Recovery After Surgery
- Healthcare Operations and Scheduling Optimization
- Advances in Oncology and Radiotherapy
- Hepatocellular Carcinoma Treatment and Prognosis
- Palliative Care and End-of-Life Issues
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Surgical Simulation and Training
Augusta University
2023-2024
University of Chicago
2021-2024
Yale University
2023-2024
University of Chicago Medical Center
2023
University of California, Irvine
2023
University of Illinois Chicago
2022
Anesthesiology and Surgical Oncology Research Group
2021
All India Institute of Medical Sciences
2020
To investigate the role of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay in informing recurrence patients with peritoneal metastases (PM) from colorectal (CRC) and high-grade appendix (HGA) cancer after curative cytoreductive surgery hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).Over 50% CRC/HGA-PM recur optimal CRS-HIPEC. The limited sensitivity axial imaging diagnostic biomarkers is significant cause delay detection initiation further therapies. Plasma ctDNA...
Importance Advance directive (AD) designation is an important component of advance care planning (ACP) that helps align with patient goals. However, it underutilized in high-risk surgical patients cancer, and multiple barriers contribute to the low AD rates this population. Objective To assess association early palliative integration changes among cancer who underwent surgery. Design, Setting, Participants This cohort study was a retrospective analysis prospectively maintained registry adult...
PURPOSE High-grade appendiceal adenocarcinomas (HGAA) with peritoneal metastases (PMs) are associated poor survival. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a novel treatment approach for unresectable HGAA-PM. However, its influence on immunogenomic profiles has not yet been fully explored. MATERIALS AND METHODS We obtained 79 samples of metastatic tumor deposits from patients diagnosed HGAA and performed whole-exome sequencing, RNA immunoprofiling before after HIPEC. Tumor...
PURPOSE Conventional surveillance methods are poorly sensitive for monitoring appendiceal cancers (AC). This study investigated the utility of circulating tumor DNA (ctDNA) in evaluating systemic therapy response and recurrence after surgery AC. METHODS Patients from two specialized centers who underwent tumor-informed ctDNA testing (Signatera) were evaluated to determine association between detection. In addition, accuracy detection during diagnosis complete cytoreductive (CRS) grade 2-3...
Next-generation sequencing (NGS) personalizes cancer treatments. In this study, we analyze outcomes based on NGS testing for colorectal (CRC) and high-grade appendiceal adenocarcinoma (HGA) with peritoneal metastases.Retrospective review of genomic analyses in patients CRC or HGA metastases at a high-volume center from 2012 to 2019.Ninety-two (57 CRC, 35 HGA) were identified. Overall survival was longer (52.8 vs. 30.5 months, p = 0.03), though rates cytoreductive surgery hyperthermic...
Unresectable appendiceal mucinous neoplasms (AMNs) with extensive peritoneal dissemination cause significant morbidity and have limited treatment options. We evaluated a novel combination of Celecoxib Myrtol in treating such AMNs.Patients recurrent AMNs disease treated daily regimen 200 mg 1200 Standardized were included. Progression-free survival (PFS) overall (OS) calculated, carcinoembryonic antigen (CEA) trends compared pretreatment post-treatment terms percentage change.Thirteen...
Plain Language Summary Patients with colorectal cancer that has spread to the lining of abdomen (peritoneum) benefit from surgery remove all cancer. The addition certain types intra‐abdominal chemotherapy during improves survival for select patients.